Blood Plasma Derivatives Market Size, Demand & Analysis 2028

Blood Plasma Derivatives Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand’s Diseases, and Others), and End User (Hospitals, Clinics, and Others)

Publication Month : Mar 2023

  • Report Code : TIPRE00007250
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 209
Inquire Before Buy

PRICING

$4550

$3640

[Research Report] The blood plasma derivatives market is expected to reach US$ 51,119.24 million by 2028 from US$ 29.886.12 million in 2022; it is estimated to record a CAGR of 9.4% from 2022 to 2028.  

Plasma derivatives are obtained from explicit plasma proteins by the cycle of fractionation. Blood plasma derivatives contain a high amount of proteins, salts, minerals, hormones, vitamins, and protease inhibitors. Thus, they are commonly used to destroy viruses that trigger bleeding disorders, hepatitis B, hepatitis C, hemophilia A, immunodeficiency, hypogammaglobulinemia, hemophilia B, and human immunodeficiency virus.

The blood plasma derivatives market is segmented on the basis of type, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics, along with the competitive landscape analysis of the world's leading market players.

Blood Plasma Derivatives Market - 

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Blood Plasma Derivatives Market: Strategic Insights

blood-plasma-derivatives-market
Market Size Value inUS$ 29.886.12 million in 2022
Market Size Value byUS$ 51,119.24 million by 2028
Growth rateCAGR of 9.4% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Lucrative Regions for Blood Plasma Derivatives Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Market Insights – Blood Plasma Derivatives Market

Increasing Usage of Immunoglobulin G in Multiple Treatments to Offer Opportunities for Blood Plasma Derivatives Market in Coming Years

Immunoglobulin G (IgG) therapies are highly used to treat primary immune deficiency caused by genetic defects. The demand for IgG has been increasing steadily for the last few years due to the increasing awareness of IgG therapy. Based on controlled trials done by Network Meta Analysis (NMA), IgG therapy has been approved for the treatment of guillain-barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and dermatomyositis. IgG therapies are also effective for treating myasthenia gravis exacerbations and stiff-person syndrome. In addition, it provides convincing efficacy in autoimmune disorders such as epilepsy, neuromyelitis, and autoimmune encephalitis.

  • In 2022, Grifols entered an agreement with Canadian Blood Services. This agreement accelerate self-sufficiency in immunoglobulins for Canada. Under the agreement, Grifols will work with Canadian Blood Services to gradually increase the sourcing of plasma in Canada to reach volumes to 2.4 million grams of Ig medicines annually by 2026.
  • In 2021, the Food and Drug Administration (FDA) approved Cutaquig for medical use. It is used as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients of 2 years and above. Cutaquig is a ready-to-use immune globulin solution for subcutaneous infusion. The product is available in 1g, 1.65g, 2g, 3.3g, 4g, or 8g single-use vials.
  • In August 2020, Kedrion Biopharma (Italy) began improving a plasma-inferred treatment for treating COVID-19 patients. The treatment could be accessible to patients in three to a half years.

A large proportion of IgG is used in specialties outside of immunology, such as oncology, neurology, hematology, and rheumatology. Compared to all, neurology is the fastest-growing specialty in the global market. The Immunoglobulin G market growth is attributed to its approval for on-label use for chronic inflammatory demyelinating polyneuropathy (CIDP) followed by its off-label use in secondary immune deficiencies caused by lymphoma, myeloma, and leukemia and the certain immunosuppressive therapies esp. B-cell targeting therapies. Thus, the wide range of IgG usage in multiple treatments for on-label and off-label prescriptions will drive IgG demand across the world in the coming years.

End User Insights

Based on end user, the global blood plasma derivatives market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period. The increasing number of hospital admissions and a rising prevalence of von Willebrand disease, immunodeficient disorders, and hemophilia are projected to drive market growth for the hospital segment during the forecast period. Moreover, emerging nations are witnessing huge demand for advanced hospital settings to cope with the increasing patient pool and rising public health concerns. Furthermore, various immunoglobulin replacement therapies are conducted in hospitals to observe the doses and adverse events related to the therapy and to monitor clinical outcomes of the product. Hospitals are primary centers for providing immunoglobulin replacement therapies, which are being developed using new technologies. Patients receiving immune globulin therapies in hospitals perceive the advantages of greater safety, closer monitoring, and support from health professionals and experts. Thus, benefits provided by hospitals, such as proper patient-centric care and availability of reimbursement facilities, are expected to fuel market growth for the segment during the forecast period.

Blood Plasma Derivatives Market, by End User – 2022 and 2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Product launches and mergers and acquisitions are among the highly adopted strategies by the global blood plasma derivatives market players. A few of the recent key product developments are listed below:

  • In April 2022, Grifols announced the acquisition completion of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG. Tiancheng (Germany) Pharmaceutical Holdings AG is a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG. Following the Public Takeover Offer (PTO) completion and the acquisition closing, Grifols controls 96.20% of the voting rights and holds 69.72% of the share capital of Biotest AG.

Blood Plasma Derivatives – Market Segmentation

Based on type, the blood plasma derivatives market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The market for the immunoglobulin segment is further segmented into IgG, IgM, IgA, IgD, and IgE. By application, the blood plasma derivatives market is segmented into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The market, by end user, is segmented into hospitals, clinics, and others. Based on geography, the blood plasma derivatives market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Company Profiles – Blood Plasma Derivatives Market

  • Grifols, S.A.
  • SK Plasma Co., Ltd.
  • Fusion Healthcare
  • Biotest AG
  • Green Cross Corp
  • Kedrion
  • LFB S.A.
  • Octapharma AG
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Application, and End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is the blood plasma derivative?

Blood plasma is the liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains blood pressure and helps exchange important minerals such as sodium and potassium for maintaining the body's pH balance. Plasma derivatives are products manufactured from human plasma using plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

What are the driving factors for the global blood plasma derivative market across the world?

The factors that are driving the growth of market are increasing prevalence of blood disorders across the world followed by rising geriatric population. However, high cost of blood plasma therapy followed by complicated reimbursement policies are the major factor hampering the growth of the market.

Who are the major players in market the blood plasma derivative market?

The blood plasma derivative market majorly consists of the players such as Grifols, S.A., SK Plasma Co., Ltd., Fusion Healthcare, Biotest AG, Green Cross Corp, Kedrion, LFB S.A., Octapharma AG, CSL Limited, and Takeda Pharmaceutical Company Limited.

Which segment is dominating the blood plasma derivative market?

The blood plasma derivative market is analyzed in the basis of type, application, and end use. Based on type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held the largest share of the blood plasma derivative market size, and it is anticipated to register the highest CAGR.

The List of Companies - Blood Plasma Derivatives Market

  1. Grifols SA
  2. SK Plasma Co Ltd
  3. Octapharma AG
  4. Monobind Inc
  5. Intas Pharmaceuticals Ltd
  6. Fusion Health Care Pvt Ltd
  7. Takeda Pharmaceutical Co Ltd
  8. CSL Behring LLC
  9. LFB SA
  10. Kedrion SpA

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Blood Plasma Derivatives Market